News

PipelineReview.com46m
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Findings demonstrate ATYR2810’s anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer.
PipelineReview.com47m
AP Biosciences Presents Preclinical Data on p95HER/CD137 T-Cell Engager at American Association of Cancer Research Annual Meeting
TAIPEI, Taiwan I April 29, 2025 I AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative ...
PipelineReview.com3h
Bayer Initiates Phase I Study Targeting GPC3 With Actinium-225 Radiopharmaceutical in Patients With Advanced Hepatocellular Carcinoma
WHIPPANY, NJ, USA I April 29, 2025 I Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted ...
PipelineReview.com3h
Potential First-in-Class Data from Preclinical Program for STX-003, a Programmable mRNA Therapy to Treat Solid Tumor Cancers
Proof-of-concept shows mRNA genetic circuitry able to target expression of IL-12 to tumors when systemically delivered ...
PipelineReview.com10d
Akeso’s Ebdarokimab ( IL – 12/IL – 23 Dual – Targeted Monoclonal Antibody) Approved in China for Moderate – to – Severe Plaque Psoriasis
HONG KONG, China I April 18, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal ...
PipelineReview.com10d
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
PARIS, France and TARRYTOWN, NY, USA I April 18, 2025 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of ...
PipelineReview.com12d
Sabin Begins Marburg Vaccine Trial in U.S.
WASHINGTON, DC, USA I April 16, 2025 I The Sabin Vaccine Institute has launched a multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine ...
PipelineReview.com13d
Radiance Announces First Patient Dosing in Phase 1 Clinical Trial of its Next Generation ROR-1 Targeted ADC for Hematologic and Solid Malignancies
BOSTON, MA, USA I April 15, 2025 I Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug ...
PipelineReview.com12d
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
GENEVA, Switzerland I April 17, 2025 I Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of ...
PipelineReview.com13d
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
MELBOURNE, Australia and INDIANAPOLIS, IN, USA I April 16, 2025 I Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces ...
PipelineReview.com13d
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild ...
PipelineReview.com11d
Endevica Bio Announces First Patient Dosing in Phase 2 Trial in Patients with Stage 4 Metastatic Colorectal Cancer
NORTHBROOK, IL, USA I April 17, 2025 I Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose ...